NCT07027488View on ClinicalTrials.gov

AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Advanced Melanoma and Normal or ImpairedAdvanced Melanoma
Interventions
DRUG

AB821

AB821 will be administered via IV infusion using weight-based dosing. Patients will receive the drug at a dose escalation every two weeks for up to 52 cycles.

Trial Locations (1)

06510

RECRUITING

Yale University, New Haven

Sponsors
All Listed Sponsors
collaborator

Asher Biotherapeutics, Inc.

INDUSTRY

lead

Yale University

OTHER

NCT07027488 - AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter